34633-08-4

Upstream product

• 1071-46-1 hydrogen ethyl malonate 
• 15164-44-0 p-(iodophenyl)carboxaldehyde 
• 140-88-5 ethyl acrylate 
• 1514-50-7 4-iodobenzenediazonium tetrafluoroborate 
• 623-73-4 diazoacetic acid ethyl ester 
• 2351-50-0 4-iodostyrene 
• 109-94-4 formic acid ethyl ester 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 688-49-3 ethyl (diethoxyphosphino)acetate 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 555-16-8 4-nitrobenzaldehdye 
• 24393-61-1 ethyl (E)-3-(4-nitrophenyl)-2-propenoate 
• 5048-82-8 (E)-ethyl 3-(4-aminophenyl)acrylate 

Downstream Products

• 238760-82-2 3-ethoxycarbonyl-4-(4-iodophenyl)pyrrole 
• 692277-77-3 ethyl (E)-3-[4-(8,8-dimethyl-5-p-tolyl-7,8-dihydro-2-naphthylselanyl)phenyl]acrylate 
• 113641-76-2 (E)-4-iodocinnamic acid 
• 161634-74-8 (2E)-3-(4-iodophenyl)-prop-2-en-1-ol 
• 157126-75-5 4-iodobenzenepropanoic acid,ethyl ester 
• 134208-99-4 3-(4-iodophenyl)-2-propenol 

Relevant academic research and scientific papers

A One-Pot Synthesis of α,β-Unsaturated Esters From Esters

A convenient method for reductive Horner–Wadsworth–Emmons (HWE) olefination is described. The E-selective HWE homologation of various esters to α,β-unsaturated esters was readily achieved and gave the desired products in good-to-moderate yields under mild conditions. The one-pot reaction proceeds through an in situ generated aldehyde, formed via the partial reduction of an ester with lithium diisobutyl-t-butoxyaluminum hydride. The formation of cyclized metal acetal and subsequent decompose to the aldehyde for the olefination was found to be a crucial step in this C2-carbon homologation protocol.

Photoinduced Oxidative Alkoxycarbonylation of Alkenes with Alkyl Formates

A photoinduced oxidative alkoxycarbonylation of alkenes initiated by intermolecular addition of alkoxycarbonyl radicals has been demonstrated. Employing alkyl formates as alkoxycarbonyl radical sources, a range of α,β-unsaturated esters were obtained with good regioselectivity and E selectivity under ambient conditions.

CRYSTAL FORM OF ESTROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR

Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer.

Highly Enantioselective Synthesis of Functionalized Glutarimide Using Oxidative N-Heterocyclic Carbene Catalysis: A Formal Synthesis of (?)-Paroxetine

A simple yet highly effective approach toward enantioselective synthesis of trans-3,4-disubstituted glutarimides from readily available starting materials is developed using oxidative N-heterocyclic carbene catalysis. The catalytic reaction involves a formal [3 + 3] annulation between enals and substituted malonamides enabling the production of glutarimide derivatives in a single chemical operation via concomitant formation of C-C and C-N bonds. The reaction offers easy access to a broad range of functionalized glutarimides with excellent enantioselectivity and good yield. Synthetic application of the method is demonstrated via formal synthesis of (?)-paroxetine and other bioactive molecules.

INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT

Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.

Silver-Catalyzed Cross-Olefination of Donor and Acceptor Diazo Compounds: Use of N-Nosylhydrazones as Diazo Surrogate

The cross-olefination reaction of donor and acceptor diazo compounds was explored. The use of N-nosylhydrazones as diazo surrogates and the dependence on silver catalysis were crucial for the reaction development. A variety of (hetero)aryl N-nosylhydrazones and α-diazo esters, amides, and phosphonates were compatible, and the functionalized alkene products were afforded in good to high yields with moderate (Z)/(E) selectivities. The experimental and DFT calculation results suggest that the cross-selectivity is due to selective activation of the silver catalyst for donor diazo compounds.

Synthesis of polystyrene-supported Pd(II)-NHC complex derived from theophylline as an efficient and reusable heterogeneous catalyst for the Heck-Matsuda cross-coupling reaction

The polystyrene-supported palladium(II)-N-heterocyclic carbene complex PS-NHC-Pd(II) was successfully synthesized from theophylline as an environmentally benign NHC precursor, using chloromethylated polystyrene resin. The PS-NHC-Pd(II) complex was characterized by various techniques including Fourier transform infrared spectroscopy (FTIR), energy dispersive X-ray spectroscopy (EDX), thermal analysis (TGA-DTG), inductively coupled plasma (ICP), and CHN elemental analysis. The morphology of the polymer beads was also studied using scanning electron microscope. The polymer supported Pd(II)-NHC complex exhibits excellent catalytic activity and stability for the Heck-Matsuda cross-coupling reaction under mild conditions. A variety of arenediazonium tetrafluoroborate salts was coupled with the olefinic substrates in ethanol, in the presence of the 0.9 mol% of the catalyst to afford the corresponding cross-coupling adducts in high yields under aerial conditions. Moreover, the heterogeneous catalyst can be easily recovered by simple filtration and reused for seven cycles without significant loss in its activity.

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Approximately 80% of breast cancers are estrogen receptor alpha (ER-α) positive, and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges. Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor. Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents. However, fulvestrant suffers from poor pharmaceutical properties and must be administered by intramuscular injections that limit the total amount of drug that can be administered and hence lead to the potential for incomplete receptor blockade. We describe the identification and characterization of a series of small-molecule, orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized. The lead compound 11l (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):